New drug shows promise for rare lung condition in early trial
NCT ID NCT00993408
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new drug called ACT-293987 (NS-304) in 43 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the lungs. The trial had two parts: first, a single dose to check how it affects blood flow, then 21 weeks where some people got the drug and others got a placebo. The goal was to see if the drug is safe and improves blood vessel function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACT-293987 (NS-304)
What this could lead to
If it works, this could point toward a new treatment option for pulmonary arterial hypertension, helping to control the disease and improve symptoms.
What could go wrong
This is a small, early Phase 2 study with only 43 people. It is designed to test safety and basic effectiveness, so results may not lead to a proven treatment. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Respiratory Medicine, Hannover Medical School
Hanover, 30625, Germany
-
Gasthuisberg University Hospital, Pneumology
Leuven, 3000, Belgium
-
Hammersmith Hospital
London, W12 0HS, United Kingdom
-
Hopital Antoine Beclere, Pneumologie
Paris, France
-
Hospital Sant'Orsola Malpighi, Cardiology's Department
Bologna, 40138, Italy
-
Instytut Gruzilcy i Chorob Pluc, Klinika Chorob Wewnetrznych Klatki Piersiowej
Warsaw, 01-138, Poland
-
Medizinische Universitat Wien, Universitatsklinik fur Innere Medizin II, Kardiologie
Vienna, 1090, Austria
-
Semmelweis University, Clinic of Pulmonology
Budapest, H-1125, Hungary